全文获取类型
收费全文 | 3148643篇 |
免费 | 232291篇 |
国内免费 | 4869篇 |
专业分类
耳鼻咽喉 | 44858篇 |
儿科学 | 103831篇 |
妇产科学 | 88069篇 |
基础医学 | 462192篇 |
口腔科学 | 88167篇 |
临床医学 | 281024篇 |
内科学 | 604120篇 |
皮肤病学 | 69069篇 |
神经病学 | 249079篇 |
特种医学 | 120272篇 |
外国民族医学 | 818篇 |
外科学 | 478177篇 |
综合类 | 66743篇 |
现状与发展 | 12篇 |
一般理论 | 1076篇 |
预防医学 | 244116篇 |
眼科学 | 74237篇 |
药学 | 236846篇 |
10篇 | |
中国医学 | 6170篇 |
肿瘤学 | 166917篇 |
出版年
2018年 | 34113篇 |
2017年 | 25631篇 |
2016年 | 28807篇 |
2015年 | 32674篇 |
2014年 | 45859篇 |
2013年 | 69307篇 |
2012年 | 95489篇 |
2011年 | 101755篇 |
2010年 | 60489篇 |
2009年 | 57026篇 |
2008年 | 96306篇 |
2007年 | 102877篇 |
2006年 | 104086篇 |
2005年 | 101258篇 |
2004年 | 97154篇 |
2003年 | 93684篇 |
2002年 | 91170篇 |
2001年 | 140695篇 |
2000年 | 144317篇 |
1999年 | 121726篇 |
1998年 | 35892篇 |
1997年 | 31576篇 |
1996年 | 31945篇 |
1995年 | 30077篇 |
1994年 | 27890篇 |
1993年 | 26219篇 |
1992年 | 95797篇 |
1991年 | 93834篇 |
1990年 | 91938篇 |
1989年 | 88977篇 |
1988年 | 82194篇 |
1987年 | 80713篇 |
1986年 | 76341篇 |
1985年 | 73175篇 |
1984年 | 54595篇 |
1983年 | 46693篇 |
1982年 | 28008篇 |
1981年 | 25056篇 |
1979年 | 51060篇 |
1978年 | 36262篇 |
1977年 | 30615篇 |
1976年 | 29190篇 |
1975年 | 31819篇 |
1974年 | 37834篇 |
1973年 | 36273篇 |
1972年 | 34294篇 |
1971年 | 32339篇 |
1970年 | 29927篇 |
1969年 | 28618篇 |
1968年 | 26617篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
Platelets are needed to prevent or arrest bleeding and aggregate at the site of injury upon vascular damage. Platelets express receptors for estrogens which might affect the function of the platelets and their hemostatic ability. The aim was to identify possible differences in platelet function related to age, gender, and phases of the menstrual cycle by use of impedance aggregometry with Multiplate. In the first part of the study, platelet function was assessed in 60 healthy individuals (30 men and 30 women) in each of three age groups (20–25, 40–45, and 60–65 years). In the second part of the study, the platelet function was analyzed on four occasions during the menstrual cycle in women without oral contraceptives (OCs) (n = 17) and compared to 19 women on OCs and 18 men of similar age (20–40 years). For the women on OCs, aggregation was analyzed once during the tablet-free week and once late during the period with OCs. The men were sampled once. Women of younger age (<45 years) had significantly higher agonist-induced aggregation response than both men and post-menopausal women (60–65 years). The agonist-induced aggregation response did not differ between phases of the menstrual cycle or OC use. The results suggest that estradiol and/or progesterone affect spontaneous aggregation since it was found to be lowest in the mid-luteal phase. Spontaneous aggregation was significantly lower in women on OCs than in both men and women without OCs. Our findings indicate that fertile age is associated with higher aggregation response capacity of the platelets, possibly to prevent excessive bleeding during menstruation, but this response capacity is not altered during the menstrual cycle or by use of OCs. 相似文献
42.
43.
44.
Amy L. Judd Kathryn L. Beck Christopher McKinlay Ashleigh Jackson Cathryn A. Conlon 《Maternal & child nutrition》2020,16(1)
Dietary assessment in infants is challenging but necessary to understand the relationship between nutrition and growth and development. Currently no simple, validated methods exist to assess nutrient intake in New Zealand (NZ) infants. Therefore, this study aimed to assess the relative validity and reproducibility of a Complementary Food Frequency Questionnaire (CFFQ) to determine nutrient intakes of NZ infants. Ninety‐five parent–infant pairs (infant age 10 ± 1 months) completed the CFFQ twice (CFFQ‐1 and CFFQ‐2), 4 weeks apart (to assess reproducibility). A 4‐day weighed food record (4dWFR) was collected between CFFQ administrations (to assess validity). Validity and reproducibility were assessed for intakes of energy and 18 nutrients using Bland–Altman analysis, Pearson's correlation coefficients, cross‐classification, and weighted Kappa (κ). The CFFQ showed acceptable validity: Nutrients from the CFFQ were comparable with the 4dWFR (bias, 9–28%), correlation between methods ranged from r = .18 (saturated fat) to r = .81 (iron; mean r = .52), 54% (mean) of participants were correctly classified (range 39% to 67%), and 7.1% (mean) misclassified into opposite tertiles (range 2.1% to 14.7%). There was acceptable agreement between the CFFQ and 4dWFR (κ = 0.20–0.60). The CFFQ showed good reproducibility: Correlations ranged from r = .34 (folate) to r = .80 (zinc); for 16 nutrients, >50% of participants were correctly classified, and for all nutrients, <10% of participants were grossly misclassified. All nutrients showed acceptable to good agreement (κ > 0.20). The CFFQ has acceptable relative validity and good reproducibility for assessing nutrient intake in NZ infants aged 9–12 months, making it a useful tool for use in future research. 相似文献
45.
Widder Randolf A. Lappas Alexandra Rennings Corinna Hild Matthias Roessler Gernot F. Dietlein Thomas S. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(11):2581-2581
Graefe's Archive for Clinical and Experimental Ophthalmology - The published online version contains mistake as the author's first name and last name have been interchanged as "Hild... 相似文献
46.
47.
48.
49.
50.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献